Clinical Trials Logo

Metastatic Solid Tumor clinical trials

View clinical trials related to Metastatic Solid Tumor.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05071183 Terminated - Clinical trials for Advanced Solid Tumor

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Start date: September 23, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1b/2 Study of Repotrectinib in Combination with Other Anticancer Therapies for the Treatment of Subjects with KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)

NCT ID: NCT04849273 Terminated - Clinical trials for Non-Small Cell Lung Cancer

A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

Start date: July 28, 2021
Phase: Phase 1
Study type: Interventional

A phase 1, first-in-human, open-label study to evaluate the safety, tolerability, PK, and efficacy of the novel ALK inhibitor TPX-0131 in pretreated subjects with ALK+ advanced or metastatic non-small cell lung cancer (NSCLC).

NCT ID: NCT04393454 Terminated - Cancer Clinical Trials

Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy

Start date: June 3, 2020
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of sirolimus by estimating the overall response rate (ORR) as assessed by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1) in patients with metastatic dMMR solid cancer after immunotherapy (either due to disease progression or to inability to tolerate treatment).

NCT ID: NCT04161391 Terminated - Clinical trials for Non Small Cell Lung Cancer

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Start date: December 6, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring RET mutations or alterations. The study consists of three portions: 1) Phase 1 Dose Escalation and Food Effect Sub-study, and 2) Phase 1 dose expansion and 3) Phase 2 efficacy evaluation.